Compare PWRL & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PWRL | DCTH |
|---|---|---|
| Founded | N/A | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 523.7M | 578.4M |
| IPO Year | 2025 | 2015 |
| Metric | PWRL | DCTH |
|---|---|---|
| Price | $11.22 | $16.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 118.7K | ★ 685.2K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.54 |
| Revenue Next Year | N/A | $33.15 |
| P/E Ratio | ★ N/A | $428.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.21 | $8.12 |
| 52 Week High | $16.31 | $17.42 |
| Indicator | PWRL | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 37.43 | 66.18 |
| Support Level | $10.21 | $10.16 |
| Resistance Level | $12.35 | $17.42 |
| Average True Range (ATR) | 0.67 | 0.82 |
| MACD | 0.06 | 0.18 |
| Stochastic Oscillator | 42.92 | 86.98 |
Powerlaw Corp is a non-diversified, closed-end management investment company. The Fund's investment objective is long-term capital appreciation. It seeks to achieve its investment objective by investing in the equity and equity-linked securities of a concentrated portfolio of approximately 12 to 15 late-stage technology companies.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.